Surgical Menopause After Ovarian or Breast Cancer: What Women Are Not Being Told
Surgical menopause after cancer treatment can change far more than fertility or hormone levels. This personal and evidence-informed blog post explores the sudden loss of ovarian hormones, the impact on cognition, mood, identity, sleep, cardiovascular and bone health and why so many women feel profoundly unprepared for what happens next.
Table of Contents
What I Witnessed - and Why This Article Exists
Understanding the Difference: Surgical, Medically-Induced and Natural Menopause
A Note on Younger Women
What Abrupt Hormone Loss Actually Does to the Body
The Mind Nobody Prepared Us For: Cognitive and Psychological Impact
The Professional Self: Work, Identity and Invisible Capacity Loss
Cancer Survivorship and the Care Gap Nobody Names
The Workplace and the Law: What Women and Employers Need to Know
What Good Support Looks Like - and How to Advocate for It
What Coaching Can and Cannot Do
FAQ
A Final Word
This article combines personal experience with evidence-informed discussion around surgical menopause after cancer treatment. It is not a substitute for individual medical advice.
1. What I Witnessed - and Why This Article Exists
I want to start with something personal.
My wife was 49 when she was diagnosed with ovarian cancer. She underwent a laparotomy, a hysterectomy, removal of her cervix, and a bilateral salpingo-oophorectomy - the surgical removal of both ovaries and fallopian tubes - among other things. The surgery was extensive and necessary. The team who performed it were skilled. We were, and remain, deeply grateful.
But nobody - not before the surgery, not during the immediate recovery, not at the early follow-up appointments - sat down and explained clearly what the removal of her ovaries would mean for the rest of her life. Before surgery, decisions about MHR/HRT were necessarily held in suspension: what could be offered would depend entirely on what the surgical findings showed. That is medically appropriate. What was harder to understand was the silence that followed once those findings were known.
My wife had been using MHT/HRT before her diagnosis - an oestrogen patch and progesterone. After surgery, with a hysterectomy and BSO now complete, the picture changed. It was she who asked the surgeon directly, at her one-month post-operative appointment, whether she could resume oestrogen therapy. Because the surgical findings indicated a borderline ovarian tumour, the answer was yes - and she restarted her oestrogen patch. Progesterone was no longer clinically required for endometrial protection, as she no longer had a uterus. But that information - the answer, the plan, the pathway - came because she asked for it. Not because a pathway existed to offer it.
It was also at that one-month appointment, only because she asked, that she was told the service had a menopause nurse and was offered a referral. She said yes, of course she did.
She waited three years for that appointment.
In the meantime, she continued to receive cervical smear reminders from her GP.
Her cervix had been surgically removed.
When she needed to discuss testosterone - a conversation that matters enormously for women after bilateral oophorectomy - she had to advocate for that herself too.
And in the years since surgery, she has navigated night sweats that arrive without warning and take the rest of the night with them. A fatigue that is not tiredness - it is something heavier, something that doesn't lift. Moods that are harder to reach. A flatness that is not who she was. And a grief that has no clear name - for a part of herself that is gone, for the version of her body she had before, for the capacity that has changed.
She is also still here. She is well. She is a cancer survivor. And she deserves better than what she received.
I tell this story not to criticise individuals within the system. I tell it because her experience is not unusual. It is, in my work and in the evidence, depressingly common.
This article is for every woman who has lived that gap.
2. Understanding the Difference: Surgical, Medically-Induced and Natural Menopause
Before exploring the evidence, it matters to be precise - because these are not the same experience and treating them as equivalent does real harm.
Natural Menopause
Natural menopause is a gradual biological process. Oestrogen and progesterone production by the ovaries declines over years - typically across a perimenopause transition lasting anywhere from two to twelve years before periods stop entirely. This gradual transition allows some degree of physiological adaptation, even when symptoms are significant.
Surgical Menopause
Surgical menopause occurs when the ovaries are removed - whether as part of a cancer operation, a risk-reducing procedure, or other surgery. Menopause is immediate. There is no perimenopause. There is no transition. Hormone levels that were normal one day are absent the next. The biological impact of this abruptness is not merely psychological: it is physiological, neurological and systemic.
Critically, the ovaries produce more than oestrogen and progesterone. They are a significant source of testosterone. Bilateral oophorectomy causes a sudden and substantial reduction in ovarian oestrogen, progesterone and testosterone production - a loss that natural menopause does not replicate in the same abrupt way.
Medically-Induced Menopause
Medically-induced menopause can occur as a consequence of cancer treatment - through chemotherapy, radiotherapy, or hormonal therapies. Aromatase inhibitors, used in breast cancer treatment, work by blocking the peripheral conversion of androgens to oestrogen, producing a marked suppression of circulating oestrogen. In premenopausal women they are used alongside ovarian suppression. GnRH agonists, sometimes used in treatment, can also induce a temporary or sustained menopausal state by suppressing ovarian function.
For premenopausal women who undergo chemotherapy, treatment-related premature ovarian insufficiency may occur - sometimes temporary, sometimes permanent.
Each of these pathways creates a different clinical picture and each requires an individualised approach to management. They are not one thing. They should not be managed as one thing.
A Note on Younger Women
Much of the public conversation about surgical and medically-induced menopause focuses on women in their late forties and early fifties. But cancer does not observe age boundaries. Women are diagnosed with ovarian cancer, cervical cancer and breast cancer at 28, at 32, at 38 - often in the middle of career-building years, sometimes before they have completed or even begun their families.
For a woman who undergoes bilateral oophorectomy at 34, surgical menopause carries a distinct set of consequences. The bone loss that accumulates from premature oestrogen withdrawal over decades rather than years is considerably more significant. The cardiovascular risk associated with early loss of oestrogen is greater. The cognitive implications of long-term oestrogen deprivation beginning before natural menopause age are more pronounced in the research. [PMID: 20965156]
And then there is the grief that the evidence does not fully capture: the grief of infertility arriving alongside cancer, often with no time or space to process it. The relationship disruption that abrupt hormonal change can bring when a woman is in her thirties and her partner, her body and her sense of future have all changed simultaneously. The career interruption - not at a point of relative professional establishment, but at the stage of building, climbing, establishing.
Younger women navigating surgical or medically-induced menopause often find that the support, the literature and the clinical pathways were not designed with them in mind. That invisibility matters. If this is you, or someone you are supporting, everything in this article applies - and the urgency of appropriate hormonal and medical management is, if anything, greater.
3. What Abrupt Hormone Loss Actually Does to the Body
When the ovaries are removed, the body loses its primary source of oestrogen, progesterone and a major portion of its testosterone supply virtually overnight. The physiological consequences are wide-ranging, significant, and - critically - often improvable or partially manageable with appropriate medical and supportive care.
It is important to state clearly at the outset: experiences vary widely. Some women experience severe and persistent symptoms after surgical or medically-induced menopause, while others experience fewer ongoing difficulties. This article reflects the range of what women can face - not a predetermined course for every individual. Equally, MHT/HRT is not appropriate or safe for every woman after cancer treatment and all treatment decisions must always be individualised, involving both oncology and menopause expertise.
Vasomotor Symptoms
Hot flushes and night sweats - the most widely recognised menopause symptoms - can be considerably more severe after surgical menopause than after natural menopause, due to the abruptness of hormone withdrawal. For my wife, the night sweats arrived immediately after surgery and have remained a semi-persistent feature of her nights. These symptoms are not merely uncomfortable. They fragment sleep at its deepest, most restorative stages and the cumulative effect of that disruption is physiological - not a matter of attitude or resilience. If you want to understand why menopause disrupts sleep and what actually helps, that is explored in depth separately - but the short answer is this: disrupted sleep has cascade effects across every other system: mood, cognition, metabolism, immune function, cardiovascular health. [PMID: 20965156]
Bone Health
Oestrogen is fundamental to bone density maintenance. Its sudden loss accelerates bone resorption and significantly increases the risk of osteoporosis and fracture - particularly when surgical menopause occurs before the age of natural menopause. Women who undergo bilateral oophorectomy before 45 without receiving MHT/HRT have substantially higher rates of osteoporosis. [PMID: 27433858] This is not a distant risk. It accumulates from the point of surgery.
Women who undergo early surgical menopause may benefit from bone density assessment via DEXA scanning - particularly where MHT/HRT is not possible or where additional osteoporosis risk factors are present. This is a concrete, guideline-supported aspect of survivorship care that is worth discussing proactively with your medical team, rather than waiting until a fracture risk becomes apparent.
Cardiovascular Health
Oestrogen has recognised cardioprotective effects, particularly when initiated close to the time of menopause - a relationship sometimes described as the "timing hypothesis." Its abrupt loss after surgical menopause before natural menopause age is associated with adverse changes in lipid profiles, blood pressure and vascular function. Women who undergo surgical menopause before natural menopause age and do not receive MHT/HRT have been found to have elevated cardiovascular risk compared to naturally postmenopausal women. [PMID: 19034050 & PMID 34880044] This is one of the reasons NICE and BMS guidance supports HRT for women with premature ovarian insufficiency and surgical menopause before 51, unless there are specific contraindications.
Genitourinary Symptoms
Genitourinary syndrome of menopause - vaginal dryness, atrophy, urinary urgency, recurrent infections, discomfort and pain - affects a significant proportion of surgically menopausal women and is frequently undertreated. Unlike vasomotor symptoms, which may ease over time, genitourinary symptoms often worsen without treatment. For women whose cancer type permits localised oestrogen treatment, this can be addressed. Current guidance increasingly supports shared decision-making around low-dose vaginal oestrogen in selected women with severe genitourinary symptoms where non-hormonal measures have failed - including, in some circumstances, women with a history of breast cancer, under specialist guidance. For those whose oncology team advises against hormonal treatment of any kind, navigating these symptoms requires careful, ongoing support with a specialist who understands the full picture.
Libido, Intimacy and Testosterone Loss
The loss of ovarian testosterone production is often the least-discussed consequence of bilateral oophorectomy - and for many women, one of the most personally significant. Testosterone contributes significantly to sexual desire and sexual function, and the evidence base for testosterone therapy in hypoactive sexual desire disorder in postmenopausal women is stronger than for many other menopause-related symptoms. Some women also report changes in energy, motivation and sense of vitality after abrupt testosterone loss, though the evidence in these areas is less established. Its sudden reduction after surgical menopause can be profound and disorienting. Women frequently describe a loss not merely of physical desire but of something harder to name - a flatness, a disconnection from themselves.
Current evidence supports the use of testosterone for low sexual desire in postmenopausal women, including those with surgically-induced menopause. [PMID: 31488288] It is worth noting that in the UK, testosterone prescribing for women is currently off-label and is usually undertaken by clinicians with experience in menopause care - typically via a menopause specialist rather than a GP. The evidence around testosterone in menopause - what it does, who it helps and how to access it - is worth understanding in full. Yet the conversation itself often requires women to initiate it themselves. .
Fatigue and Body Composition
The fatigue that follows abrupt hormone loss is qualitatively different from ordinary tiredness. My wife describes it as persistent and daily - a weight that is present before the day begins and that sleep does not fully resolve. It is a physiological exhaustion, compounded by disrupted nights, the physical demands of surgical recovery, and the sustained effort of continuing to function at full capacity in a body that is working entirely differently than it once did. Body composition changes - including increased abdominal adiposity and reduced muscle mass - are common after surgical menopause and are driven by hormonal, metabolic and lifestyle factors that interact in complex ways. Evidence on [strength training after menopause] is clear that resistance exercise is one of the most effective tools available for protecting muscle mass, bone density and metabolic function - but how to approach this sustainably after cancer treatment is a different conversation from how it is typically presented.
4. The Mind Nobody Prepared Us For: Cognitive and Psychological Impact
This is the section I most want women to read. And the one most often missing from the conversation.
The most common question I hear from women after surgical menopause is some version of this: I don't feel like myself. My mind doesn't work the way it used to. Is this real, or am I imagining it?
It is real. It is not imagined. And the evidence increasingly supports it.
I watch my wife navigate this every day. She is trying to learn new things - deliberately, actively - to offset the cognitive changes she notices. She works longer hours than she did before surgery, because tasks that used to take her an hour now take considerably more. Her brain fog has not resolved. She is compensating constantly and the compensation itself is exhausting.
Oestrogen, Progesterone, Testosterone and the Brain
The brain contains receptors for oestrogen, progesterone and androgens. These hormones do not merely regulate the reproductive system - they exert direct effects on brain function, mood regulation, memory consolidation, verbal fluency, processing speed and executive function. [PMID: 21961718]
Oestrogen in particular appears to have neuroprotective functions, influencing serotonergic and dopaminergic pathways, synaptic plasticity, and aspects of cognitive function. The abrupt withdrawal of oestrogen - rather than the gradual decline seen in natural menopause - creates a neurological disruption that gradual transitions may not. The relationship between oestrogen variability and mood has been examined in perimenopausal research, suggesting that fluctuating and declining oestrogen directly affects the brain's emotional regulation systems. [PMID: 31693131]
Surgical Menopause and Cognitive Decline: What the Research Shows
The evidence linking bilateral oophorectomy before natural menopause age to cognitive outcomes has accumulated steadily. It is important to note that these associations are complex, not fully understood, and influenced by multiple factors - they do not imply inevitable or universal cognitive decline.
A large-scale Mayo Clinic cohort study reported associations between bilateral oophorectomy before natural menopause age and increased long-term risk of cognitive impairment and dementia in some women, particularly where oestrogen deprivation was prolonged. [PMID: 17012044] A subsequent meta-analysis found further associations between early bilateral oophorectomy and increased risk of cognitive decline. [PMID: 30928686]
Research suggests associations between early bilateral oophorectomy, prolonged oestrogen deprivation and later cognitive outcomes, particularly where surgery occurs well before natural menopause age. However, these relationships are complex and influenced by multiple factors, including age at surgery, indication for the procedure, cancer treatment effects, and whether oestrogen therapy was subsequently used. This is not fearmongering, and these findings do not apply uniformly to all women. They are evidence, however, that the question of hormonal management after surgical menopause has implications that extend beyond immediate symptoms - and that women deserve to be part of that conversation from the outset.
Brain Fog, Memory and Executive Function
Beyond the longer-term research, the day-to-day cognitive experience of surgical menopause is something I hear described with striking consistency - and something I observe directly.
Word-finding difficulties. Walking into a room and having no idea why. Losing the thread of conversations. Reading the same paragraph three times. An inability to hold multiple pieces of information simultaneously - when that multi-tasking capacity was, before surgery, simply assumed.
For my wife, this is not occasional. It is the background condition of her working days. She is highly capable. She knows she is highly capable. And she works considerably harder than she did before surgery to demonstrate it - to herself as much as to anyone else.
These are not trivial symptoms. They affect functioning, confidence, professional performance and quality of life. And they are frequently minimised - by healthcare providers, by employers, and often by the women themselves, who feel they should simply be grateful to have survived cancer.
If the cognitive changes of surgical or sudden menopause feel frightening or difficult to explain, my free Brain Fog Survival Guide explores practical, evidence-informed strategies that may help support concentration, memory, energy and daily functioning during midlife hormonal change.
Mood, Anxiety and Emotional Regulation
The abrupt loss of ovarian hormones can produce rapid and significant changes in mood. Anxiety that appears from nowhere. Irritability that feels disproportionate. A low mood that doesn't respond to the things that previously helped. An emotional volatility that feels foreign and frightening.
These changes are neurochemical. They are driven by the withdrawal of hormones that directly modulate the brain's mood regulation systems. They are not a sign of psychological weakness, and they are not a failure to cope with having survived cancer.
My wife and I used to cry laughing. At silly things, at shared things, at the particular frequency of absurdity that long partnerships develop. She doesn't find those things funny in the same way anymore. The humour is harder to reach. She is more often flat than not - not depressed in a clinical sense, but altered. Less herself. The woman who was, to her core, a glass-half-full person now has to work to find the glass at all. Some days she does. Some days she doesn't.
Some studies suggest depressive symptoms may be more common after surgical menopause than after natural menopause, particularly following early bilateral oophorectomy. Apathy, emotional flattening and a reduced sense of pleasure are also reported, and are likely connected to the same hormonal disruption of dopaminergic and serotonergic systems. These symptoms deserve the same clinical attention as the physical ones. They rarely receive it.
The Grief Nobody Names
There is a particular loss that sits beneath all of this that is almost never acknowledged in clinical settings, and that I want to name here directly.
It is the grief of losing a part of yourself.
Not the cancer - the surgery. The removal of organs that were part of being a woman, in the most fundamental biological sense. The loss of the hormones those organs produced. The loss of the capacity - cognitive, emotional, physical - that those hormones supported. The loss of the person you were before, who laughed more easily, who felt sharper, who moved through the world with a lightness that has become harder to find.
This grief is real. It is not self-pity. It is not ingratitude. It is not a failure to appreciate being alive. It is a legitimate, unwitnessed loss - and it deserves space, acknowledgement, and compassion.
Many women describe feeling that they cannot grieve this because they are supposed to feel grateful. Survival and grief are not mutually exclusive. You can be profoundly thankful to be here and also mourn what changed. Both are true. Both are allowed.
The Role of Progesterone: An Evolving Conversation
Women who have had a hysterectomy - as part of surgical menopause for ovarian cancer, for example - are typically prescribed oestrogen-only MHT/HRT, because progesterone is not required for endometrial protection when the uterus has been removed. This is standard, appropriate clinical practice.
My wife is in exactly this position. She takes oestrogen. She does not take progesterone for endometrial reasons - she no longer needs to. But she finds herself asking a different question: might progesterone have a role in sleep quality, mood, or cognitive function that is separate from its role in protecting the uterus?
It is a reasonable question, and an increasingly discussed one. There is a growing conversation among researchers and clinicians about whether progesterone may have neurological effects beyond the uterus. Progesterone metabolites, including allopregnanolone, interact with GABA receptors in the brain and appear to have calming, sleep-promoting and anxiolytic effects. [PMID: 23978486] Some researchers propose this may have implications for sleep quality, emotional regulation and aspects of cognitive function.
If you are experiencing menopause and anxiety that feels disproportionate or hard to explain, this is an area worth raising with your menopause specialist.
The evidence here, however, remains emerging and is not definitive. This is not a case for all women without a uterus to take progesterone - individual responses vary considerably, and this requires personalised clinical assessment. Nor should it be read as a criticism of oestrogen-only prescribing, which is clinically appropriate for women without a uterus. For some women, symptom review and treatment adjustment may still be needed over time - and that conversation is worth having with a specialist who is genuinely up to date with the evolving evidence. This remains an evolving area of research that warrants more clinical attention than it currently receives.
These cognitive and psychological changes do not stay at home. For many women, they follow them into the workplace, shaping confidence, performance and professional identity in ways that are rarely recognised.
Many women are never told how suddenly surgical menopause can affect sleep, anxiety, cognition and confidence. If this sounds familiar, download my free guide:
“3am Wake-Ups in Menopause: Why They Happen and What Helps.”
5. The Professional Self: Work, Identity and Invisible Capacity Loss
There is a particular grief that rarely gets named in any clinical or workplace conversation.
It is the grief of the woman who returns to her career after cancer treatment - who has, by any measure, survived something enormous - and finds that the version of herself who sits at that desk is not the same version who left.
She is slower to process. She finds sustained concentration effortful in a way it never was before. She sits in meetings and notices the gap between what she is able to contribute in the moment and what she knows she is capable of. She compensates. She prepares more. She does not say anything, because she is supposed to be the success story. She is alive.
My wife returned to work in UK higher education after her surgery. There were no adjustments offered after her short phased return. No proactive conversation. No acknowledgement that she was returning not simply from cancer surgery but from an abrupt surgical menopause with ongoing, daily consequences. She managed. She is still managing. She has since moved roles - in part because the environment she returned to did not adapt to meet her where she was.
This is not a story about weakness. It is a story about a system that failed to see what was in front of it.
Many women describe surgical or early menopause as feeling unlike themselves - emotionally, mentally and physically. If you are struggling to make sense of the changes happening in midlife, this free guide offers practical support, reassurance and a clearer understanding of what may be happening.
What Women in Cognitively Demanding Roles Describe
Reduced cognitive stamina - the ability to sustain high-level mental performance across a working day - is among the most commonly reported functional consequences of abrupt hormone loss. Working memory, processing speed, the ability to hold multiple strands of complex information simultaneously, to think clearly under pressure, to recover quickly from cognitive demands - these capacities are all influenced by the hormonal environment of the brain.
For women in leadership, healthcare, education, law, finance, senior management or any cognitively demanding role, this is not an abstract concern. It is a daily professional reality that many are managing in silence.
The cumulative toll of compensating - of working harder to produce the same output, of constantly masking cognitive fatigue, of managing sensory overwhelm and disrupted sleep while maintaining professional performance - is itself exhausting. It compounds the underlying physiological depletion.
The Grief of Changed Capacity
This is also an identity issue, not just a functional one.
Many women's professional competence is deeply bound up with their sense of self. To feel less sharp, less resilient, less able to perform at the level they once did - after an experience as enormous as cancer and major surgery - can produce a quiet, private grief that is rarely witnessed or validated by others.
The pressure to bounce back, to demonstrate that survival is triumph, to perform wellness and recovery, sits alongside the reality of a body and a brain navigating a profound endocrine disruption.
Many women describe feeling guilty for struggling. They feel they should only feel grateful. Gratitude and struggle are not mutually exclusive. Survival and suffering are not mutually exclusive. Both can be true at once.
What the Evidence Supports
Research on cancer-related cognitive impairment - sometimes referred to as "chemobrain" or "cancer fog" - has established that treatment-related cognitive effects are real, measurable and functionally significant. [PMID: 30928686] The additional contribution of surgically-induced hormonal change compounds this for women who have undergone oophorectomy as part of cancer treatment.
Survivorship fatigue - distinct from ordinary tiredness and persisting well beyond active treatment - is a well-documented phenomenon in cancer survivorship research. Its interaction with hormonal change, sleep disruption and psychological burden creates a complex picture that is not adequately captured by "cancer survivor" as a single category.
What these women need is not to be told they should feel better by now. They need support that recognises the full physiological and psychological picture.
6. Cancer Survivorship and the Care Gap Nobody Names
When active cancer treatment ends, it can feel - from the outside - like the story is over. The patient is discharged. The appointments thin out. The system moves on.
For many women navigating surgical or medically-induced menopause, the story is not over. It has changed shape.
The Continuity Problem
My wife was told at her one-month post-operative appointment - because she asked - that a menopause nurse referral was available. She accepted immediately. She waited three years for that first appointment.
Three years is not an anomaly. It is a reflection of a system in which cancer survivorship care and menopause care exist in separate silos, with no guaranteed mechanism for joining them up. Oncology teams are focused, appropriately, on cancer management and survival. Menopause care, where it exists, is delivered through different pathways - GP, gynaecology, dedicated menopause clinics - with variable waiting times, variable expertise in cancer-related menopause, and no proactive handover.
The result is women falling through gaps. Women who have survived cancer being told to wait months - or years - for a first menopause appointment. Women who ask about testosterone being told it isn't offered. Women whose cognitive and psychological symptoms are attributed to the emotional aftermath of cancer, when the underlying driver may be a treatable endocrine disruption. Women receiving cervical smear reminders after their cervixes have been surgically removed.
These experiences are reported by many women navigating cancer-related menopause care - and they deserve to be taken seriously.
The Informed Consent Problem
For women facing cancer surgery that involves oophorectomy, the focus of pre-operative conversations is, understandably, on the cancer itself - staging, prognosis, surgical risk, recovery. The menopause consequences of ovary removal may be mentioned briefly, or may not be adequately explored at all.
When surgical findings then determine what is and is not possible hormonally, and when the conversation about those options depends on the patient thinking to ask, we have an informed consent problem. Women deserve to understand, before surgery, the full range of physiological consequences of bilateral oophorectomy - not as a source of additional fear, but as preparation for what comes next.
Preparation does not prevent difficulty. But it can make it less disorienting, less isolating, and more navigable.
What Better Survivorship Care Looks Like
Better survivorship care includes a proactive menopause pathway that begins before or immediately after surgery or active treatment - not three years later. It includes explicit discussion of HRT options where clinically appropriate, testosterone where relevant, bone and cardiovascular health monitoring, cognitive and psychological support, and clear signposting to specialist services.
It includes not sending cervical smear reminders to women whose cervixes have been removed.
These are not extraordinary asks. They are basic continuity of care.
7. The Workplace and the Law: What Women and Employers Need to Know
Note: The following section is educational and is not legal advice. Women who need specific guidance about their workplace situation should consult a qualified employment lawyer or HR professional.
The Functional Reality
Surgical and medically-induced menopause can produce functional impacts at work that are substantial and that may persist for months or years without appropriate medical support. Cognitive difficulties - reduced processing speed, impaired working memory, difficulty concentrating, word-finding problems - combine with fatigue, sleep disruption, mood instability, anxiety and the physical demands of recovery from cancer treatment.
Many women attempt to sustain previous levels of performance while managing these impacts without disclosure. The psychological cost of doing so is high. And the absence of disclosure often means the absence of support.
My wife returned to a workplace after surgery with no adjustments, no proactive conversation and no acknowledgement that she was navigating an ongoing endocrine disruption on top of cancer recovery. She is not alone in this. It is a pattern I see repeatedly, across sectors and seniority levels. Women quietly compensating, quietly struggling, quietly concluding that they are the problem - when the problem is the absence of support.
The UK Legal Framework
In the United Kingdom, the Equality Act 2010 provides that disability discrimination is unlawful. A person is considered disabled under the Act where they have a physical or mental impairment that has a substantial and long-term adverse effect on their ability to carry out normal day-to-day activities.
Under the Equality Act 2010, cancer is treated as a disability from the point of diagnosis - this means the disability discrimination provisions apply from diagnosis, regardless of whether cancer causes disability in the conventional sense. Where menopause symptoms are severe, long-term and substantially impact daily functioning, they may in some circumstances also meet the definition of disability, though this is assessed on an individual basis and is not automatic. Employment tribunals in the UK have increasingly considered menopause in the context of disability and discrimination claims, reflecting growing recognition of the functional impacts involved.
The Health and Safety at Work etc. Act 1974 places a duty on employers to ensure, so far as is reasonably practicable, the health, safety and welfare of employees - which includes psychological wellbeing.
Recent employment tribunal cases, alongside guidance from ACAS, CIPD and the Equality and Human Rights Commission, reflect growing recognition of menopause-related workplace impacts. Menopause does not yet have standalone statutory protection, but it is covered indirectly through sex, disability and age discrimination provisions under the Equality Act 2010.
Employers are encouraged to consider reasonable adjustments for employees experiencing significant symptoms - including flexible working, adjusted workloads, temperature adjustments, access to facilities, and phased returns after treatment-related absence.
Practical Workplace Considerations
ACAS and the CIPD both provide guidance on supporting employees through menopause. The Equality and Human Rights Commission has noted that employers should take menopause seriously as a workplace issue. Menopause-aware workplace policies, manager training, and psychologically safe environments where women feel able to discuss their situation without stigma are increasingly recognised as both a moral and a business imperative. For a fuller overview of what [menopause at work support] can look like in practice, that is covered separately.
For women returning to work after cancer treatment and surgical menopause, a phased return is often appropriate. Occupational health referral, a supportive conversation with a line manager and clear communication about temporary adjustments can make the difference between a sustainable return and a return that compounds existing depletion.
Women should not need to reach crisis point - or change jobs - before these conversations happen.
If you're a manager supporting an employee through menopause, cancer recovery or surgical menopause, download my free Manager's Guide to Menopause Conversations at Workto understand practical adjustments, supportive conversations and how to create a psychologically safe workplace.
What Employers Can Do
The most important thing employers can do is create the conditions in which women feel safe to say: I am managing something significant, and I may need some support. For HR teams and organisations, my freeMenopause Workplace Assessment helps identify gaps in manager confidence, employee awareness, workplace culture and menopause support systems.
That means menopause-aware policies. It means managers who have been educated enough not to respond with discomfort or dismissal. It means occupational health that understands the specific context of cancer-related surgical menopause - not just the more commonly discussed natural menopause in the context of a working woman in her early fifties.
Returning to work after cancer treatment does not mean the physiological consequences of abrupt menopause have ended. An employee who appears to have "recovered" from cancer may still be managing a complex, ongoing endocrine disruption - compensating daily for cognitive changes that are invisible to everyone around her. Understanding that - and acting accordingly - is both humane and legally prudent.
8. What Good Support Looks Like - and How to Advocate for It
With Your Medical Team
If you have undergone surgical or medically-induced menopause as part of cancer treatment, you deserve a proactive menopause review - not one you have to request repeatedly, but one that is part of your survivorship care.
Current NICE guidance (NG23) recommends that women with premature ovarian insufficiency - which includes surgical menopause before 51 - are offered HRT to protect bone, cardiovascular and cognitive health, unless there are specific contraindications. The British Menopause Society supports this position and publishes specific guidance on menopause management following cancer treatment. Management decisions should ideally involve both menopause and oncology expertise, particularly where the indication for surgery was cancer. If you have not been offered a menopause review, you are entitled to ask for it.
Ask specifically to be referred to a menopause specialist - particularly one with experience in cancer-related menopause.
Questions worth asking:
Given my surgical history and cancer type, what HRT options are appropriate for me?
What monitoring do you recommend for my bone density and cardiovascular health?
Should I be referred for a DEXA scan to assess bone density?
Can we discuss testosterone - what the evidence says and whether it might be appropriate in my situation?
What are the options for genitourinary symptoms?
Are there cognitive or psychological support pathways available to me?
Can I be referred to a menopause specialist if this is outside your area of expertise?
The British Menopause Society (thebms.org.uk) provides a Find a Menopause Specialist directory and publishes guidance specifically on menopause after cancer treatment. Ovacome, the ovarian cancer support charity, and Breast Cancer Now both provide relevant survivorship support and information, including guidance on menopause management after their respective diagnoses.
If your symptoms are being dismissed, or you are told that what you are experiencing is "just the after-effects of cancer treatment" or "normal ageing," you are entitled to seek a second opinion. You are also entitled to bring a completed symptom diary to your appointments. Documented, dated, specific symptoms are harder to dismiss than verbal descriptions in a ten-minute consultation.
The Symptom Diary
Tracking symptoms - type, severity, time of day, duration, functional impact - for two to four weeks before a medical appointment gives your clinician meaningful data. It also gives you a record of your own experience that is harder to minimise or attribute to anxiety.
Include: sleep, mood, hot flushes, night sweats, cognitive symptoms, fatigue, joint pain, libido, genitourinary symptoms, and any functional impacts on work or daily life.
9. What Coaching Can and Cannot Do
I want to be clear about scope, because I think it matters.
I am a certified Nutrition and Health Coach, trained through IINH and accredited by UKIHCA. I do not diagnose. I do not prescribe. I do not replace oncology teams, menopause specialists, GPs or psychologists. I do not advise on HRT or cancer treatment.
What I can do is work with women navigating the space between medical management and daily life - the gap where many women are left once the prescriptions are written or the appointments are concluded.
That space is large, and it matters enormously.
It includes: understanding what is happening in your body and why. Building nutrition habits that support energy, sleep, blood sugar regulation and bone health. Finding sustainable movement approaches that work within your actual capacity rather than the capacity you had before surgery. Learning to regulate your nervous system in a body that is working differently than it once did. Rebuilding routines and rhythms that support recovery. Exploring how sense of self and daily identity can shift after surgical menopause, and how to build sustainable habits that support confidence and functioning. Navigating the return to work with realistic expectations and practical strategies.
I work in this space partly because of what I have witnessed in my own home. I know what it looks like to live alongside someone navigating this. I know what falls through the gaps. And I know that the gap between "medically managed" and "genuinely supported" is wider than it should be.
None of this replaces medical care. All of it complements it.
If you are managing the daily reality of surgical or medically-induced menopause - whether you are recently post-surgery or years into a journey that still feels unresolved - and you want support within that coaching scope, I offer a free 30-minute Menopause Clarity Call.
Even if we decide coaching isn't right for you, you'll leave with clarity.
Book your free Menopause Clarity Call →
10. Frequently Asked Questions
Is surgical menopause the same as natural menopause? No. Surgical menopause - resulting from the removal of both ovaries - is immediate rather than gradual. Hormone levels drop abruptly rather than declining over years. This abruptness can produce more severe and sudden symptoms than natural menopause, and carries specific long-term health implications for bone density, cardiovascular health and cognitive function that require proactive management.
Can women use MHT/HRT after ovarian cancer? For many women treated for epithelial ovarian cancer, MHT/HRT may be considered appropriate and is not universally contraindicated, and current BMS and NICE guidance supports its use where surgical menopause has occurred before the age of natural menopause, given the cardiovascular, bone and cognitive health implications of prolonged oestrogen deprivation. For women with borderline ovarian tumours, HRT may also be appropriate. However, clinical decisions depend on the individual's cancer type, staging, surgical findings and oncology team's assessment. No general statement covers all cases, and the decision must always be made on an individualised basis with input from both oncology and menopause specialist teams.
Can women use MHT/HRT after breast cancer? This is an area of ongoing clinical discussion. Systemic MHT/HRT is generally not recommended for women with hormone receptor-positive breast cancer. However, localised vaginal oestrogen for genitourinary symptoms is increasingly being considered for some women with breast cancer where quality of life impact is severe and non-hormonal measures have failed, under careful specialist guidance. Women with hormone receptor-negative breast cancer may have different options. All decisions must involve the oncology team and be individually assessed.
What is medically-induced menopause? Menopause caused by medical treatment rather than natural ageing or surgery - for example, through chemotherapy causing ovarian failure, through GnRH agonists used in cancer treatment, or through aromatase inhibitors used in breast cancer treatment, which suppress oestrogen by blocking peripheral conversion of androgens.
Why might cognitive symptoms be worse after surgical menopause than natural menopause? Because the brain adapts to gradual hormonal change differently than to abrupt change. Oestrogen has neuroprotective functions and influences neurotransmitter systems including serotonin and dopamine. Its sudden withdrawal, rather than gradual decline, produces a neurological disruption that has been associated with greater cognitive impact than natural menopause in some research. [PMID: 30928686] These associations are complex and influenced by multiple factors, but the pattern is consistent enough to warrant serious clinical attention.
What is the role of testosterone after bilateral oophorectomy? The ovaries are a significant source of testosterone. After bilateral oophorectomy, ovarian testosterone production falls substantially. The strongest evidence base for testosterone therapy in postmenopausal women is in the treatment of hypoactive sexual desire disorder (low sexual desire causing distress). Some women also report improvements in energy and sense of vitality, though evidence in these areas is less established. Women should raise the question of testosterone specifically with their menopause specialist - this conversation often does not happen unless the woman initiates it.
Can surgical menopause count as a disability under the Equality Act 2010? Where symptoms have a substantial and long-term adverse effect on day-to-day activities, they may in some circumstances meet the definition of disability under the Equality Act 2010. This is assessed on an individual basis and is not automatic. Under the Act, cancer is treated as a disability from the point of diagnosis, meaning disability discrimination protections apply from that point. Women who believe their rights may not be being upheld should seek specialist employment advice.
What specialist support is available? The British Menopause Society's Find a Specialist directory (thebms.org.uk) provides access to accredited menopause specialists and publishes guidance on cancer-related menopause. Ovacome provides support for ovarian cancer survivors. Breast Cancer Now provides support including menopause guidance for breast cancer survivors. ACAS provides employer and employee guidance on menopause in the workplace.
11. A Final Word
My wife is doing well. The road since surgery has not been simple, and it has not been straight. The night sweats are still there. The fatigue is still daily. The brain fog that makes familiar things take longer is still the background condition of her working life. The flat days still come.
But she is here. She is well. She continues - with determination, with self-advocacy, with a resilience she has had to rebuild from different materials than the ones she had before. She is relearning things, deliberately. She is asking questions that should have been answered years ago. She is doing the work that the system did not do for her.
What I carry from watching her navigate this is a clear and quiet conviction.
Women who face surgical or medically-induced menopause after cancer deserve better than many currently receive. Not in every case, and not from every clinician - some centres provide genuinely excellent survivorship menopause care. But the current standard of survivorship menopause care remains inconsistent, and the preparation is not good enough.
Survival matters enormously. It is the first thing, the necessary thing. Nobody disputes that.
But quality of life matters too. Cognitive health matters. Professional capacity matters. Intimacy matters. Sleep matters. Laughter matters. Feeling like yourself matters.
Women do not need to choose between gratitude for survival and honest acknowledgement of what is hard. Both are true. Both are allowed.
If you are in the middle of this - recently post-surgery, or years into a journey that still feels unresolved - I want you to know: what you are experiencing is real. It is physiological. It is not weakness. It is not failure. And you are not imagining it.
You deserve support that sees the whole picture. Not just the cancer-free scan. The whole of you.
If this article resonated with you, and you’re navigating the physical, emotional or cognitive impact of menopause or surgical menopause, you don’t have to figure it out alone.
I offer evidence-informed menopause health coaching focused on helping women better understand their symptoms, support their long-term health and rebuild confidence in midlife health and wellbeing.
You can explore my services or get in touch here.
For a broader overview of how hormonal changes affect sleep, mood, cognition, energy and physical symptoms during menopause, see my guide to menopause symptoms and hormone changes.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Nothing in this article should be taken as a recommendation to start, stop or change any medication or medical treatment. All decisions regarding MHT/HRT, cancer treatment and hormone management must be made in consultation with your own medical team. The author is a Nutrition and Health Coach and not a medical doctor. UKIHCA scope of practice applies throughout.
References
PMID 20965156 Rocca WA, Grossardt BR, Shuster LT.
Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity.
Neurodegener Dis. 2010;7(1-3):163-166.PMID: 30928686 Georgakis MK, Kalogirou EI, Diamantaras AA, et al.
Age at menopause and duration of reproductive period in association with dementia and cognitive function: a systematic review and meta-analysis. Eur J Epidemiol. 2019;34(4):397-411.PMID: 27433858 Hibler E, Kauderer J, Greene MH, et al.
Bone Loss Following Oophorectomy Among High-Risk Women: An NRG Oncology/Gynecologic Oncology Group study.
Menopause. 2016;23(11):1226-1231.PMID: 21961718Greendale GA, Derby CA, Maki PM.
Perimenopause and cognition. Obstet Gynecol Clin North Am. 2011;38(3):519-535.PMID: 23978486 Bäckström T, Haage D, Löfgren M, et al.
Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons.
Neuroscience. 2011;191:46-54 PMID 31488288 Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Sex Med. 2019;16(9):1331-1337.
PMID: 31693131 Joffe H, Hall JE, Soares CN, et al.
Influence of estradiol variability and progesterone on mood in perimenopausal women. J Clin Endocrinol Metab. 2020;105(3).PMID: 19034050 Rivera CM, Grossardt BR, Rhodes DJ, et al.Increased cardiovascular mortality after early bilateral oophorectomy.
Menopause. 2009;16(1):15-23PMID: 34880044 Cusimano MC, Chiu M, Ferguson SE, et al. Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study. BMJ. 2021;375:e067528
Ehlin von Kartaschew Å, Dahm-Kähler P, Rodriguez Wallberg K, Holmberg E, Flöter-Rådestad A.
Menopausal hormone therapy after ovarian cancer: A 10-year survival analysis in premenopausal women. Acta Obstet Gynecol Scand. 2026. doi:10.1111/aogs.70242PMID 17012044 Walter A Rocca et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study
PMID 23615642 Weber MT et al. Cognition in perimenopause: the effect of transition stage.
